These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17466615)

  • 1. Is cortical bone hip? What determines cortical bone properties?
    Epstein S
    Bone; 2007 Jul; 41(1 Suppl 1):S3-8. PubMed ID: 17466615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging.
    Duan Y; Beck TJ; Wang XF; Seeman E
    J Bone Miner Res; 2003 Oct; 18(10):1766-74. PubMed ID: 14584886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
    Compston JE
    Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
    Seeman E
    Bone; 2007 Sep; 41(3):308-17. PubMed ID: 17644058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
    Christiansen P
    APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
    Boyce RW; Paddock CL; Franks AF; Jankowsky ML; Eriksen EF
    J Bone Miner Res; 1996 May; 11(5):600-13. PubMed ID: 9157775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
    Riggs BL; Parfitt AM
    J Bone Miner Res; 2005 Feb; 20(2):177-84. PubMed ID: 15647810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.
    Iwamoto J; Matsumoto H; Takeda T; Sato Y; Liu X; Yeh JK
    Calcif Tissue Int; 2008 Aug; 83(2):121-8. PubMed ID: 18543014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary hyperparathyroidism and the skeleton.
    Mosekilde L
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):1-19. PubMed ID: 18167138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys.
    Fox J; Miller MA; Newman MK; Recker RR; Turner CH; Smith SY
    Bone; 2007 Sep; 41(3):321-30. PubMed ID: 17573250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.
    Seeman E
    Osteoporos Int; 2003; 14 Suppl 3():S2-8. PubMed ID: 12730770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone remodeling at the endocortical surface of the human femoral neck: a mechanism for regional cortical thinning in cases of hip fracture.
    Power J; Loveridge N; Lyon A; Rushton N; Parker M; Reeve J
    J Bone Miner Res; 2003 Oct; 18(10):1775-80. PubMed ID: 14584887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss.
    Parfitt AM; Mathews CH; Villanueva AR; Kleerekoper M; Frame B; Rao DS
    J Clin Invest; 1983 Oct; 72(4):1396-409. PubMed ID: 6630513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
    Geoffroy V; Paschalis EP; Libouban H; Blouin S; Ostertag A; Chappard D; Cros M; Phipps R; de Vernejoul MC
    Calcif Tissue Int; 2011 Jun; 88(6):464-75. PubMed ID: 21455736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging concepts in osteoporosis and bone strength.
    Rubin CD
    Curr Med Res Opin; 2005 Jul; 21(7):1049-56. PubMed ID: 16004672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.